Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Tumor-infiltrating lymphocytes (TILs) play a pivotal role in the immune response against cancer. These lymphocytes infiltrate tumor tissues and are often associated with improved patient prognoses in various cancers. At Creative Biolabs, our advanced IHC-based service provides comprehensive profiling of TIL phenotypes, employing state-of-the-art instrumentation and expertly designed multiparametric panels.
At Creative Biolabs, we are committed to providing cutting-edge TIL phenotypic profiling services that leverage our expertise in IHC. Our IHC services utilize state-of-the-art techniques to visualize and characterize immune cell populations directly within tissue samples, allowing for precise assessment of their distribution, activation status, and interactions with tumor cells. With our expert guidance and high-quality staining protocols, researchers can uncover critical information about immune responses in various cancers, paving the way for innovative therapeutic approaches and personalized medicine.
We employ state-of-the-art IHC techniques to stain tissue samples for various TIL markers, including CD8, CD4, FoxP3, and PD-1. This allows for the precise identification and localization of different TIL populations within the tumor microenvironment.
Our service provides an extensive analysis of TIL phenotypes, covering a wide array of subsets such as CD8+, CD4+, and Tregs. This comprehensive profiling helps in understanding the TIL heterogeneity and predicting responses to immunotherapies.
Recognizing that each research project is unique, we offer customized IHC panels tailored to specific research needs. Whether you require a focus on specific TIL populations or additional markers to assess tumor characteristics, our team will work closely with you to develop the ideal panel.
Our service incorporates multiplex IHC, allowing the simultaneous detection of multiple biomarkers. This capability provides a more detailed picture of TIL interactions and their functional status in situ, which is invaluable for comprehensive immune profiling.
Our team of experienced pathologists and immunologists provides comprehensive consultation services. We ensure that you understand the implications of the data, offering detailed reports that contextualize the findings within your research framework.
At Creative Biolabs, our comprehensive service provides end-to-end support for the development of TIL-based immunotherapies, including TIL isolation, robust expansion protocols, and thorough phenotypic profiling through IHC. We are committed to offering clients a detailed look into the makeup of expanded TILs. Through IHC, we assess the expression of activation markers, exhaustion markers, and subsets like CD8+ T cells, which are crucial for ensuring the TILs remain potent and functionally capable.
If you're seeking a reliable partner to support your TIL therapy program with phenotypic profiling services for expanded TILs, we're here to help. Contact us to discuss how our IHC services support your TIL therapy project.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
